MK

Manisankari Kumaravadivel

Active Director Director DIN 11495906
DIN 11495906 First appointment Jan 2026
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 2 active board seats
Total affiliations 2 Since Jan 2026
Shareholding value β€’β€’β€’β€’ Premium profile

About Manisankari Kumaravadivel

Data last updated:

Manisankari Kumaravadivel is a Director at Nanmei Pharmaceuticals Private Limited (since 2026) and Director at Tracell Medtech Private Limited (since 2026).

DIN 11495906
Primary Designation Director
First Appointment 20 Jan 2026

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director08 Jul 20262026Active
Tracell Medtech Private Limited U72100TZ2026PTC037566
Director20 Jan 20262026Active

Board colleagues of Manisankari Kumaravadivel

Directorship timeline

Open interactive timeline →
Tracell Medtech Private Limited
Nanmei Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Manisankari Kumaravadivel

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Manisankari Kumaravadivel

Manisankari Kumaravadivel currently holds 2 directorships: Nanmei Pharmaceuticals Private Limited (Director, since 08 Jul 2026); Tracell Medtech Private Limited (Director, since 20 Jan 2026).

Manisankari Kumaravadivel was first appointed on 20 Jan 2026 as Director at Tracell Medtech Private Limited.

The current boards of Manisankari Kumaravadivel's companies include Kandasamy Kumaravadivel (Nanmei Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available